Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119247) titled 'Efficacy and safety of different durations of keverprazan-based quadruple therapy for Helicobacter pylori eradication: An open-label, multicenter, randomized, noninferiority trial' on Feb. 25.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: NanJing First Hospital
Condition:
Helicobacter pylori infection
Intervention:
Group A:keverprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, doxycycline 100 mg twice daily, colloidal bismuth pectin 300 mg twice daily for 7 days
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-25
Target Sample Size:...